Abstract

The development of computational models for assessing the transfer of chemicals across the placental membrane would be of the utmost importance in drug discovery campaigns, in order to develop safe therapeutic options. We have developed a low-dimensional machine learning model capable of classifying compounds according to whether they can cross or not the placental barrier. To this aim, we compiled a database of 248 compounds with experimental information about their placental transfer, characterizing each compound with a set of ∼5.4 thousand descriptors, including physicochemical properties and structural features. We evaluated different machine learning classifiers and implemented a genetic algorithm, in a five cross validation scheme, to perform feature selection. The optimization was guided towards models displaying a low number of false positives (molecules that actually cross the placental barrier, but are predicted as not crossing it). A Linear Discriminant Analysis model trained with only four structural features resulted to be robust for this task, exhibiting only one false positive case across all testing folds. This model is expected to be useful in predicting placental drug transfer during pregnancy, and thus could be used as a filter for chemical libraries in virtual screening campaigns.

Highlights

  • Drug prescribing in pregnancy remains a complex and controversial issue for both pregnant women and clinicians (Leong et al, 2019)

  • After an extensive feature selection process and the evaluation of different models, we present in this work a robust Linear Discriminant Analysis (LDA) classifier trained with only four features that exhibits an excellent performance

  • Considering that the odds of classifying a molecule that crosses the placenta as not crossing must be reduced to a minimum, we chose F1/2 as the metric to evaluate performance, favoring models that have a low number of FPs; while having a high false rate of predictions is always undesirable, it would be highly risky in this specific case

Read more

Summary

Introduction

Drug prescribing in pregnancy remains a complex and controversial issue for both pregnant women and clinicians (Leong et al, 2019). Over the past 30 years, the use of prescription drugs during the first quarter trimester of pregnancy has increased by more than 60%. This suggests that at the beginning of pregnancy, many women either present pre-chronic conditions (e.g., pre-gestational diabetes) or develop pregnancy-specific diseases (e.g., hyperemesis gravidarum, intrahepatic cholestasis of pregnancy, HELLP syndrome) which will require the administration of medications, including those which might cause fetal toxicity or teratogenesis (Eke et al, 2020).

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call